Greystone Pharmaceuticals, Inc. Scientific Advisory Board

Greystone Pharmaceuticals, Inc.’s Scientific Advisory Board (SAB) provides advice and scientific expertise to the company on an ongoing basis. The SAB is regularly informed on the progress of Greystone’s research and development projects and provides feedback as well as scientific and regulatory input. The Scientific Advisory Board is comprised of distinguished intellectuals who are leaders in the field of advanced wound care and repair.

H. Paul Ehrlich, PhD

Dr. Ehrlich is Professor of Surgery and Cellular and Molecular Physiology, Hershey Medical Center, Penn State University College of Medicine. His extensive wound research experience has been in the areas of collagen biochemistry, proteinase control mechanisms, matrix and non muscle cell interactions, mechanisms and regulations of the contraction process, mediators of inflammation and dermal damage and cell biology of wound healing and scar formation. He has been involved in the writing of over fifteen text books and monographs on wound research and has published over 140 research papers on wound healing science. Dr. Ehrlich is on the Editorial Advisory Boards of the Journal of Burn Care and Rehabilitation and of Wound Repair and Regeneration.

George R. Martin, PhD

Dr. George R. Martin served as the Senior Vice President for Scientific Affairs at FibroGen from 1994 to 2002 where he was responsible for research and development activities at FibroGen as well as coordination of external academic research programs. Prior to joining FibroGen, Dr. Martin was the Scientific Director of the National Institute on Aging (NIA), National Institutes of Health (NIH). In this position, he was responsible for managing the NIA Gerontology Research Center in Baltimore, Maryland, and directing the Intramural Research Program, a multi-disciplinary program with numerous independent laboratories and branches. Prior to accepting that position, he was Chief of the Laboratory of Developmental Biology of the National Institute of Dental and Craniofacial Research (NIDCR), NIH. Dr. Martin also served on many academic and foundation boards and as an advisor to several companies. Currently, he is working with Tissue Technologies in their wound dressing program. Dr. Martin received his Ph.D. in Pharmacology and Biochemistry from the University of Rochester and his B.A. in Chemistry from Colgate University. Over his distinguished career, Dr. Martin has trained numerous scientific investigators, received a number of honors and awards, and published over 300 articles in such areas as collagen, wound healing, developmental biology, aging, cell biology, and molecular biology.

Ronald L. Goode, PhD

Dr. Goode has served as the President and Chief Executive Officer at the biopharmaceutical companies, eXegenics, Inc., and Unimed Pharmaceuticals, Inc. He has also held key management positions at Pfizer Pharmaceuticals (Vice President of Clinical Research and Scientific Affairs, Director of Marketing Research) and at G. D. Searle & Co. (Senior Vice President of Commercial Development, President of Asia/Pacific World Area, President of Searle International). He has an extensive record of success in business development, having been responsible for many of Searle's acquisitions, including DayPro, which became Searle's largest-selling drug. Dr. Goode currently serves on the Boards of Genitope Corporation (Nasdaq: GTOP) and Hikma Pharmaceuticals PLC (London: HIK), the Business Advisory Board of ART Recherches et Technologies Avancées Inc., a Canadian medical devices company; the Board of Mercy Ships International, a charity medical organization; and other non-public boards. Dr. Goode holds a M.S. in Microbiology from the University of Memphis and a Ph.D. in Microbial Genetics from the University of Georgia.

Gregory Schultz, PhD

Dr. Gregory S. Schultz is a Professor of Obstetrics and Gynecology and a Director of the Institute for Wound Research at the University of Florida. Dr. Schultz's research focuses on the role of growth factors, cytokines and proteases in normal and chronic wound healing in skin and eye. Dr. Schultz has published more than 210 research papers, chapters and review articles, which have been cited more than 5,100 times, and he has over a dozen patents in the area of wound healing. He has received over $11 million in total grants from the National Institutes of Health, pharmaceutical companies, and the U.S. Army, and he is a consultant for multiple biotechnology companies. He is the Chair of the Wound Bed Preparation Advisory Board, and he served as President of the Wound Healing Society from 1999-2001.

Dr. Jeffrey Davidson, PhD

Dr. Davidson has an extensive background in wound healing research. He is currently the Professor of Pathology, Vanderbilt University School of Medicine and has been on the Board of Directors for the Wound Healing Society, 1994-1997, 2003-2007. He was a Senior Staff Fellow, Pulmonary Branch, National Heart, Lung, and Blood Institute (NHLBI), of the NIH, Bethesda, Maryland, 1978-1981; Associate Chief, Clinical Chemistry, VA Medical Center, Salt Lake City, Utah, 1981-1983; Asst. Prof. of Pathology, Univ. of Utah Sch. of Med., Salt Lake City, Utah, 1981-1983; Associate Chief for Research, Lab. Svc, VA Med. Ctr., Salt Lake City, Utah, 1983-1984; Associate Professor of Pathology, Univ. of Utah, Salt Lake City, Utah, 1983-1985; Associate Professor of Pathology, Vanderbilt Univ., Nashville, TN, 1986-1987; Member, Career Development Committee, Department of Veterans Affairs, 1987-1991; Ad Hoc Reviewer, Site Visitor, NIH Pathobiochemistry Study Section, 1985, 1987, 1990, 1997; Member, NIH Pathobiochemistry Study Section, 1991-1996 (Chairman 1995-1996); Visiting Scientist, Fidia Research Laboratories, Abano Terme, Italy, 1990; Associate Director for Research, W.M. Keck-Vanderbilt Free-Electron Laser Center, 1996-2000. He has published over 140 research papers on wound healing research and holds several patents in wound technology.